These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 32209330)
1. RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience. Hamdy N; Bokhary H; Elsayed A; Hozayn W; Soliman S; Salem S; Alsheshtawi K; Abdalla A; Hafez H; Hammad M Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e368-e374. PubMed ID: 32209330 [TBL] [Abstract][Full Text] [Related]
2. Gene mutations in the Ras pathway and the prognostic implication in Korean patients with juvenile myelomonocytic leukemia. Park HD; Lee SH; Sung KW; Koo HH; Jung NG; Cho B; Kim HK; Park IA; Lee KO; Ki CS; Kim SH; Yoo KH; Kim HJ Ann Hematol; 2012 Apr; 91(4):511-7. PubMed ID: 21901340 [TBL] [Abstract][Full Text] [Related]
3. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Loh ML; Sakai DS; Flotho C; Kang M; Fliegauf M; Archambeault S; Mullighan CG; Chen L; Bergstraesser E; Bueso-Ramos CE; Emanuel PD; Hasle H; Issa JP; van den Heuvel-Eibrink MM; Locatelli F; Stary J; Trebo M; Wlodarski M; Zecca M; Shannon KM; Niemeyer CM Blood; 2009 Aug; 114(9):1859-63. PubMed ID: 19571318 [TBL] [Abstract][Full Text] [Related]
4. JMML genomics and decisions. Niemeyer CM Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):307-312. PubMed ID: 30504325 [TBL] [Abstract][Full Text] [Related]
5. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. Muramatsu H; Makishima H; Jankowska AM; Cazzolli H; O'Keefe C; Yoshida N; Xu Y; Nishio N; Hama A; Yagasaki H; Takahashi Y; Kato K; Manabe A; Kojima S; Maciejewski JP Blood; 2010 Mar; 115(10):1969-75. PubMed ID: 20008299 [TBL] [Abstract][Full Text] [Related]
6. Juvenile myelomonocytic leukemia: who's the driver at the wheel? Niemeyer CM; Flotho C Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449 [TBL] [Abstract][Full Text] [Related]
8. Targeted therapy in juvenile myelomonocytic leukemia: Where are we now? De Vos N; Hofmans M; Lammens T; De Wilde B; Van Roy N; De Moerloose B Pediatr Blood Cancer; 2022 Nov; 69(11):e29930. PubMed ID: 36094370 [TBL] [Abstract][Full Text] [Related]
9. Integrated molecular profiling of juvenile myelomonocytic leukemia. Murakami N; Okuno Y; Yoshida K; Shiraishi Y; Nagae G; Suzuki K; Narita A; Sakaguchi H; Kawashima N; Wang X; Xu Y; Chiba K; Tanaka H; Hama A; Sanada M; Ito M; Hirayama M; Watanabe A; Ueno T; Kojima S; Aburatani H; Mano H; Miyano S; Ogawa S; Takahashi Y; Muramatsu H Blood; 2018 Apr; 131(14):1576-1586. PubMed ID: 29437595 [TBL] [Abstract][Full Text] [Related]
10. Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea. Kim HS; Lee JW; Kang D; Yu H; Kim Y; Kang H; Lee JM; Ahn A; Cho B; Kim S; Chung NG; Kim Y; Kim M Br J Haematol; 2021 Dec; 195(5):748-756. PubMed ID: 34590720 [TBL] [Abstract][Full Text] [Related]
11. Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations. Yoshida N; Doisaki S; Kojima S Paediatr Drugs; 2012 Jun; 14(3):157-63. PubMed ID: 22480363 [TBL] [Abstract][Full Text] [Related]
12. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. Lipka DB; Witte T; Toth R; Yang J; Wiesenfarth M; Nöllke P; Fischer A; Brocks D; Gu Z; Park J; Strahm B; Wlodarski M; Yoshimi A; Claus R; Lübbert M; Busch H; Boerries M; Hartmann M; Schönung M; Kilik U; Langstein J; Wierzbinska JA; Pabst C; Garg S; Catalá A; De Moerloose B; Dworzak M; Hasle H; Locatelli F; Masetti R; Schmugge M; Smith O; Stary J; Ussowicz M; van den Heuvel-Eibrink MM; Assenov Y; Schlesner M; Niemeyer C; Flotho C; Plass C Nat Commun; 2017 Dec; 8(1):2126. PubMed ID: 29259247 [TBL] [Abstract][Full Text] [Related]
13. Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome. Lasho T; Patnaik MM Best Pract Res Clin Haematol; 2020 Jun; 33(2):101171. PubMed ID: 32460983 [TBL] [Abstract][Full Text] [Related]
14. Somatic mosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia. Doisaki S; Muramatsu H; Shimada A; Takahashi Y; Mori-Ezaki M; Sato M; Kawaguchi H; Kinoshita A; Sotomatsu M; Hayashi Y; Furukawa-Hibi Y; Yamada K; Hoshino H; Kiyoi H; Yoshida N; Sakaguchi H; Narita A; Wang X; Ismael O; Xu Y; Nishio N; Tanaka M; Hama A; Koike K; Kojima S Blood; 2012 Aug; 120(7):1485-8. PubMed ID: 22753870 [TBL] [Abstract][Full Text] [Related]
15. Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells. Tasian SK; Casas JA; Posocco D; Gandre-Babbe S; Gagne AL; Liang G; Loh ML; Weiss MJ; French DL; Chou ST Leukemia; 2019 Jan; 33(1):181-190. PubMed ID: 29884903 [TBL] [Abstract][Full Text] [Related]
16. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia. Yoshida N; Yagasaki H; Xu Y; Matsuda K; Yoshimi A; Takahashi Y; Hama A; Nishio N; Muramatsu H; Watanabe N; Matsumoto K; Kato K; Ueyama J; Inada H; Goto H; Yabe M; Kudo K; Mimaya J; Kikuchi A; Manabe A; Koike K; Kojima S Pediatr Res; 2009 Mar; 65(3):334-40. PubMed ID: 19047918 [TBL] [Abstract][Full Text] [Related]
17. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia. Locatelli F; Algeri M; Merli P; Strocchio L Expert Rev Hematol; 2018 Feb; 11(2):129-143. PubMed ID: 29279013 [TBL] [Abstract][Full Text] [Related]